Apokyn (apomorphine hydrochloride) is a prescription drug used to treat certain symptoms of advanced Parkinson’s disease. Apokyn comes as a liquid solution for injection under the skin. It’s usually ...
APOKYN may interact with other medicines to cause serious side effects. APOKYN must be injected just under the skin and not into a vein. Patients and caregivers must receive detailed instructions in ...
Credit: Getty Images. The approval is only for the drug cartridges, which are compatible for use with the Apokyn Pen, the brand name pen injector. The Food and Drug Administration (FDA) has approved ...
TruPharma and its development and commercial partner Sage have received the Food and Drug Administration’s blessing for generic apomorphine hydrochloride cartridges 30 mg/3 mL (10 mg/mL). The ...
Apokyn ® (apomorphine hydrochloride injection) is the only therapy available in the US for the acute treatment of "off" episodes (re-emergence of Parkinson´s disease symptoms) associated with advanced ...
People with Parkinson’s disease sometimes have “off episodes” when their traditional oral drug therapy cannot help. A group of people with Parkinson’s disease gathered Tuesday afternoon to learn about ...
Sage Chemical is a privately held pharmaceutical company dedicated to developing and commercializing niche pharmaceutical products. Sage has been in business since 1999, initially distributing hard-to ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c8mz88/apokyn) has announced the addition of the "Apokyn (Parkinson's ...
Citing significant implications for patients with advanced Parkinson’s disease, as well as the broader public interest that’s at stake, the U.S. FTC filed an amicus brief in Sage Chemical Inc.’s ...
LONDON (CBS.MW) -- Mylan Laboratories said the Food and Drug Administration has approved Apokyn as a therapy for the acute, intermittent treatment of hypomobility associated with advanced Parkinson's ...
NEW YORK (MarketWatch) -- Mylan Laboratories said it was selling its U.S. and Canadian rights for its Apokyn Parkinson's disease treatment for $23 million in cash to Vernalis PLC. All obligations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results